Vanderbilt University has divulged muscarinic M1 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of pain, Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), tardive dyskinesia, Tourette syndrome, sleep disorders and cognitive disorders, among others.
Arrepath Inc. has identified UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors reported to be useful for the treatment of gram-negative bacterial infections.
Researchers from Johns Hopkins University, National Institutes of Health and University of Iowa have synthesized superstolide derivatives reported to be useful for the treatment of cancer and viral infections.
Nimbus Salacia Inc. has disclosed serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of autoimmune diseases, cancer, diabetes, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis and skin hyperpigmentation, among others.
Crossfire Oncology BV has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a serine/threonine-protein kinase PLK1 (STPK13) targeting moiety through a linker reported to be useful for the treatment of cancer, autoimmune diseases, transplant rejection, neurological disorders and inflammatory disorders.
Napa Therapeutics Ltd. has identified ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of inflammatory disorders, metabolic diseases, cancer, obesity, diabetes, rheumatoid arthritis, fibrosis and neurodegeneration, among others.
Takeda Pharmaceutical Co. Ltd. has synthesized heterocyclic compounds acting as orexin OX2 receptor (OX2R; HCRTR2) agonists reported to be useful for the treatment of narcolepsy, among others.
Humanwell Healthcare (Group) Co. Ltd. has disclosed Mas-related G-protein coupled receptor member X4 (MRGPRX4; SNSR5; SNSR6) antagonists reported to be useful for the treatment of pruritus.
Sandoz Inc. came out the big winner Nov. 18 when the U.S. Court of Appeals for the Federal Circuit wiped out $39 million in infringement damages a jury had awarded to Allergan plc. Sandoz overcame “the doubly high burden of persuading us to overturn a jury verdict of no invalidity,” the appellate court said in its precedential opinion.
RSS
